Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gillooly

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Bioorganic & Medicinal Chemistry Letters|June 28, 2011
Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitorsAlaric J Dyckman, Tianle Li, Sidney Pitt, et al.
Journal of Medicinal Chemistry|December 13, 2006
2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitorJagabandhu Das, Ping Chen, Derek Norris, et al.
Bioorganic & Medicinal Chemistry Letters|March 28, 2008
Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitorsStephen T Wrobleski, Shuqun Lin, John Hynes, et al.
Bioorganic & Medicinal Chemistry Letters|March 4, 2008
The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitorJohn Hynes, Hong Wu, Sidney Pitt, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 5, 2009
Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritisKathleen M Gillooly, Mark A Pattoli, Tracy L Taylor, et al.
Journal of Medicinal Chemistry|December 28, 2020
Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2Chunjian Liu, James Lin, Charles Langevine, et al.
Science Translational Medicine|July 26, 2019
Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domainJames R Burke, Lihong Cheng, Kathleen M Gillooly, et al.
Journal of Medicinal Chemistry|December 13, 2007
Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitorsJohn Hynes, Alaric J Dyckman, Shuqun Lin, et al.
Journal of Medicinal Chemistry|September 1, 2010
Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseasesChunjian Liu, James Lin, Stephen T Wrobleski, et al.
Journal of Medicinal Chemistry|November 30, 2004
The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinaseKaterina Leftheris, Gulzar Ahmed, Ran Chan, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Bioorganic & Medicinal Chemistry Letters|June 28, 2011
Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitorsAlaric J Dyckman, Tianle Li, Sidney Pitt, et al.
Journal of Medicinal Chemistry|December 13, 2006
2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitorJagabandhu Das, Ping Chen, Derek Norris, et al.
Bioorganic & Medicinal Chemistry Letters|March 28, 2008
Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitorsStephen T Wrobleski, Shuqun Lin, John Hynes, et al.
Bioorganic & Medicinal Chemistry Letters|March 4, 2008
The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitorJohn Hynes, Hong Wu, Sidney Pitt, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 5, 2009
Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritisKathleen M Gillooly, Mark A Pattoli, Tracy L Taylor, et al.
Journal of Medicinal Chemistry|December 28, 2020
Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2Chunjian Liu, James Lin, Charles Langevine, et al.
Science Translational Medicine|July 26, 2019
Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domainJames R Burke, Lihong Cheng, Kathleen M Gillooly, et al.
Journal of Medicinal Chemistry|December 13, 2007
Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitorsJohn Hynes, Alaric J Dyckman, Shuqun Lin, et al.
Journal of Medicinal Chemistry|September 1, 2010
Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseasesChunjian Liu, James Lin, Stephen T Wrobleski, et al.
Journal of Medicinal Chemistry|November 30, 2004
The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinaseKaterina Leftheris, Gulzar Ahmed, Ran Chan, et al.
Pageof 5